Skip to main content

Third World Access to Essential Medicines and the WTO General Council Decision 2003

Buy Article:

$32.45 plus tax (Refund Policy)


Following the Implementation of Paragraph 6 of the Doha Declaration on TRIPS and public health, Canada was the first developed country to amend its patent law, which resulted in Canada's Access to Medicines Regime (CAMR). The CAMR allowed manufacturers to manufacture generic drugs domestically and export them to developing countries with insufficient manufacturing capacity. This paper uses the case of Rwanda, which was the first developing country to take advantage of this legislation, in order to analyse how effective the CAMR and the Paragraph 6 Agreement were in ensuring that developing countries could access generic drugs.

Document Type: Research Article

Publication date: February 1, 2010

More about this publication?
  • Until 2007 the King's Law Journal was known as the King's College Law Journal. It was established in 1990 as a legal periodical publishing scholarly and authoritative Articles, Notes and Reports on legal issues of current importance to both academic research and legal practice. It has a national and international readership, and publishes refereed contributions from authors across the United Kingdom, from continental Europe and further afield (particularly Commonwealth countries and USA). The journal includes a Reviews section containing critical notices of recently published books.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more